Dai Y, Dai C, Sun T. Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review.
Int Ophthalmol 2020;
40:1587-1601. [PMID:
32103371 PMCID:
PMC7242233 DOI:
10.1007/s10792-020-01325-4]
[Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Accepted: 02/15/2020] [Indexed: 02/06/2023]
Abstract
Purpose
To review the role of inflammatory mediators in proliferative vitreoretinopathy (PVR) development and the current treatment for PVR prevention.
Methods
A PubMed search was carried out using these keywords “PVR,” “inflammatory mediators,” “growth factors,” “cytokines” and “treatment.” Studies regarding inflammatory mediators and PVR therapy were included and published up to December 2019.
Results
Inflammatory mediators, namely growth factors and cytokines, have been implicated in the occurrence and development of PVR. Among various inflammatory mediators, transforming growth factor-β, platelet-derived growth factor, interleukin-6, interleukin-8 and tumor necrosis factor-α are considered to be particularly important. In this review, we focus on the hypothesis that growth factors and cytokines are involved in the development of PVR, and current treatment for the prevention of PVR.
Conclusion
We support the hypothesis that growth factors and cytokines may participate in the complex process of PVR development. More importantly, the identification of inflammatory mediators provides novel and efficacious therapeutic targets for the treatment of PVR.
Collapse